Show MeThe three main types of colitis are ulcerative colitis, Crohn's colitis, and microscopic colitis, and they differ by which layer of the bowel wall they attack and which section of the colon they occupy. Ulcerative colitis inflames the inner mucosal lining continuously from the rectum upward. Crohn's colitis causes patchy, full-thickness inflammation that can skip segments. Microscopic colitis produces a macroscopically normal colon with visible inflammation only under a microscope. Each has a distinct age of onset, a distinct diagnostic test, and a distinct treatment ladder, which is why the label matters more than the shared symptom of diarrhea.
What Colitis Actually Means at the Tissue Level
Colitis is inflammation of the colon, and inflammation is a coordinated immune event, not simple irritation. Immune cells release cytokines such as tumor necrosis factor and interleukins, which widen blood vessels and recruit more white cells into the tissue. That cascade produces the classic quartet: redness, swelling, warmth, and pain, plus mucus and blood in the stool.
The colon's job explains the symptoms. It reabsorbs roughly 1 to 1.5 liters of water per day from the 7 to 8 liters entering it. When inflammation damages the lining, water absorption falls, so stool volume rises. When inflammation erodes the surface, blood and protein leak out.
Depth of injury separates the types. Ulcerative colitis and Crohn's colitis are macroscopic: a colonoscope sees the damage directly. Microscopic colitis is invisible to the naked eye, so biopsies are mandatory for diagnosis. In plain terms: two types scar the colon visibly, and one hides under a normal-looking surface.
Type 1: Ulcerative Colitis and Its Continuous Attack
Ulcerative colitis is a chronic immune-mediated disease that starts in the rectum and spreads proximally in an unbroken sheet. It affects only the mucosa and submucosa, never the full wall thickness, which is why fistulas and strictures are rare.
Extent defines the subtype. Proctitis involves the rectum only and accounts for roughly 30 percent of cases. Left-sided colitis reaches up to the splenic flexure in about 40 percent. Pancolitis involves the entire colon in the remaining 30 percent. Extent predicts risk: pancolitis carries a cumulative colorectal cancer risk of about 5 to 8 percent at 20 years, versus under 2 percent for proctitis.
Symptoms follow a pattern. Bloody diarrhea, urgency, and tenesmus dominate, with nocturnal bowel movements in 70 to 80 percent of flares. Cramping pain usually sits in the left lower abdomen and eases with defecation.
The mechanism is a barrier failure. Tight junctions between epithelial cells loosen, so bacteria cross into the submucosa, triggering a Th2-skewed immune response with elevated interleukin-13. The repair response is incomplete, so ulceration recurs at the same sites.
Diagnosis rests on colonoscopy with biopsy showing continuous crypt distortion, plus stool testing to exclude infection. Fecal calprotectin above 250 micrograms per gram supports active inflammation and can replace some repeat scopes.
Type 2: Crohn's Colitis and the Patchy Pattern
Crohn's colitis is Crohn's disease confined to the colon, and it appears in about 20 percent of Crohn's patients as isolated colonic disease. Another 40 to 50 percent have ileocolonic involvement, meaning the colon is part of a wider pattern.
The defining feature is transmural inflammation: it cuts through all layers of the bowel wall. That depth explains the complications unique to Crohn's: fistulas in 20 to 30 percent of patients over time, abscesses, and fibrotic strictures. Skip lesions, with normal mucosa between inflamed patches, are the endoscopic signature.
Granulomas appear on biopsy in only 15 to 25 percent of Crohn's colitis cases, so their absence proves nothing. When present, they strongly favor Crohn's over ulcerative colitis.
Pain and bleeding differ from ulcerative colitis. Right lower quadrant pain, diarrhea, and weight loss lead, and gross bleeding occurs in about half of patients versus nearly all ulcerative colitis flares. Perianal disease, including fissures and fistulas, accompanies colonic Crohn's in 15 to 25 percent.
Smoking is the sharpest environmental contrast. It doubles Crohn's risk and worsens its course, while it reduces ulcerative colitis risk, an effect documented for decades. The 2011 landmark analysis by Mahid and colleagues quantified the opposite direction for each disease.
Type 3: Microscopic Colitis, the Invisible One
Microscopic colitis is chronic watery diarrhea with a colon that looks normal on endoscopy. Diagnosis requires biopsies from the right and left colon, since the right side is more often affected. Two histologic subtypes exist: collagenous colitis, with a thickened subepithelial collagen band of at least 10 micrometers, and lymphocytic colitis, with at least 20 intraepithelial lymphocytes per 100 epithelial cells.
It accounts for 10 to 20 percent of chronic diarrhea cases in older adults undergoing colonoscopy. Incidence runs about 20 to 30 per 100,000 person-years in some northern European cohorts, and it is rising.
The demographic profile is distinctive. Median age at diagnosis is around 65, and women outnumber men by 3 to 7 to 1. Peak prevalence sits in the seventh decade, a pattern opposite to the bimodal onset of inflammatory bowel disease.
The mechanism is immune dysregulation of the mucosal surface without ulceration. Bile acid malabsorption co-occurs in roughly 40 percent of patients, which is why bile acid binders work. A drug trigger is found in a substantial minority: proton pump inhibitors, nonsteroidal anti-inflammatory drugs, selective serotonin reuptake inhibitors, and, per the 2022 World Health Organization safety communication, the diabetes drugs including GLP-1 receptor agonists. Stopping the offending drug resolves symptoms in up to 30 to 50 percent of drug-related cases.
Fecal calprotectin is usually normal or only mildly elevated, which is a key non-obvious point: microscopic colitis is not visible on inflammatory markers the way the other two are. In plain terms: a normal colonoscopy and normal calprotectin do not rule colitis out.
Side-by-Side Comparison of the Three Types
| Feature | Ulcerative colitis | Crohn's colitis | Microscopic colitis |
|---|---|---|---|
| Depth of inflammation | Mucosa and submucosa | Full thickness (transmural) | Superficial, microscopically visible |
| Distribution | Continuous from rectum | Patchy, skip lesions | Patchy, right colon favored |
| Typical age at onset | Bimodal peaks at 15-30 and 50-70 | Bimodal, similar peaks | Median around 65 |
| Blood in stool | Nearly all flares | About 50 percent | Rare |
| Fecal calprotectin | High during flares | High during flares | Usually normal |
| Colonoscopy appearance | Ulcers, continuous erythema | Patchy ulcers, sometimes strictures | Normal |
| Smoker risk | Reduced risk | Increased risk | Weak or inconsistent |
| First-line therapy | 5-aminosalicylates | Budesonide or systemic steroids | Budesonide, drug withdrawal |
| Surgery role | Curative colectomy possible | Reserved for complications | Nearly never |
The table reconciles one frequent confusion: ulcerative colitis and Crohn's colitis both raise calprotectin above 250 micrograms per gram during flares, but a value below 50 does not exclude microscopic colitis.
The Diagnostic Timeline From First Symptom to Correct Label
The type of colitis is often misassigned early, because symptoms overlap and first-line testing is limited. This timeline reflects typical paths, not rules.
| Time point | What happens | Typical finding |
|---|---|---|
| Week 0 to 2 | Symptoms begin; infection suspected | Stool cultures and C. difficile testing negative |
| Week 2 to 6 | Calprotectin and bloodwork ordered | Calprotectin above 250 favors macroscopic colitis |
| Week 4 to 12 | Colonoscopy with biopsies | Continuous vs patchy vs normal visual appearance |
| Week 6 to 16 | Histology returns | Crypt distortion, granulomas, or collagen band |
| Month 3 to 6 | Therapy trial and reassessment | Response confirms but never defines the diagnosis |
| Year 1 onward | Surveillance schedule set | Cancer risk stratification begins at 8 to 10 years for IBD |
The counterintuitive part of this timeline: histology can lag clinical suspicion by weeks, so starting treatment before biopsies return is common and appropriate when symptoms are severe, as long as biopsies are still taken.
What the Labels Get Wrong: Misconceptions and Red Flags
One common misconception is that the three types are stages of one disease. They are separate entities with different immune pathways, and a patient does not progress from microscopic colitis to ulcerative colitis.
Another is that a normal colonoscopy excludes colitis. It excludes visible colitis only, missing microscopic colitis entirely, which affects 10 to 20 percent of older adults with chronic diarrhea.
A third is that bleeding always means ulcerative colitis. About half of Crohn's colitis patients bleed, and infectious colitis also bleeds, so the symptom is a poor discriminator.
Seek urgent care for any of the following red flags:
- More than 6 to 8 bloody stools per day, suggesting severe acute colitis
- Fever above 101.5 degrees Fahrenheit with abdominal pain
- Abdominal rigidity or rebound tenderness, which can signal toxic megacolon
- Weight loss over 10 percent of body weight in 3 months
- Symptoms starting after recent antibiotic use, pointing to C. difficile
- New-onset diarrhea in a patient over 60 on a new medication
Severe acute colitis carries a colectomy rate of about 20 to 30 percent in hospitalized cases and a mortality of 1 to 2 percent, so the threshold for emergency evaluation is low.
What to Actually Do: Practical Steps by Type
For anyone with suspected colitis, three actions come first. Get a stool test to exclude infection before any immunosuppressant. Ask whether the colonoscopy included biopsies from multiple segments. Track stool frequency, blood, and weight in a simple daily log, because response to therapy is judged on trends.
For confirmed ulcerative colitis, take maintenance therapy continuously rather than only during flares, since stopping 5-aminosalicylates raises relapse risk about 3-fold. Begin surveillance colonoscopy at 8 years of disease, then every 1 to 3 years depending on risk factors. Quitting smoking is still advised for overall health, even though the ulcerative colitis association runs the other way.
For confirmed Crohn's colitis, stop smoking, which is the single highest-yield intervention and roughly doubles relapse risk. Discuss steroid-sparing therapy early, since budesonide works better for mild right-sided disease than for extensive colonic disease. Report perianal symptoms promptly, because fistulas respond best when treated within weeks.
For microscopic colitis, review every medication with a clinician before assuming a new drug is safe. Try a supervised 4 to 8 week trial off the suspected trigger. Use budesonide as first-line pharmacotherapy per the 2017 American Gastroenterological Association guidance. Add a bile acid binder if watery diarrhea persists after budesonide.
Limits of Current Knowledge and What Remains Uncertain
The causes of all three types remain incompletely understood. Genetics explain part of ulcerative colitis and Crohn's risk, with over 200 associated loci identified, but they do not predict who develops disease or when.
The microbiome hypothesis is plausible and unproven as a cause. Dysbiosis is consistently observed, but whether it triggers inflammation or results from it is unresolved. Fecal microbiota transplantation induces remission in some ulcerative colitis trials at rates around 20 to 30 percent versus 10 percent for placebo, well short of a cure.
Microscopic colitis incidence is rising faster than population aging explains, and no single cause has been confirmed. Drug triggers account for a substantial share, but idiopathic cases remain common.
Cancer surveillance intervals are extrapolated from cohort data, not randomized trials, so exact thresholds differ between the 2019 American Society for Gastrointestinal Endoscopy and British Society of Gastroenterology guidance. What is certain: the label determines the surveillance schedule, the treatment ladder, and the surgical options, which is why the three types of colitis are diagnosed with biopsies rather than symptoms alone.